Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Online ahead of print]

Opioid-induced Hypogonadism: Pathophysiology, Clinical and Therapeutics Review


Opioid-induced Hypogonadism: Pathophysiology, Clinical and Therapeutics Review

Thomas Antony et al. Clin Exp Pharmacol Physiol.


Opioids are pivotal therapeutics in the management of escalated chronic pain (moderate-severe). In the last two decades, the increased prescription rate and the prolonged usage of opioids shed light on opioid-induced endocrinopathy. Opioid-induced hypogonadism (OHG) results upon long-term opioid therapy. Clinically, patients with OHG are presented mainly by sexual dysfunction and infertility. Opioid clinical use in pain therapy is indispensable. However, the resultant sexual endocrinopathy cannot be overlooked and hence hormonal replacement therapy with regular monitoring of the patients represents a potential therapeutic strategy while avoiding opioids in patients with guaranteed long therapeutic exposure and switching to using low-dose naltrexone as alternative represents a possible prophylactic measure to ensure therapeutic compliance and secure a good life quality of patients.

Keywords: chronic pain; hormonal replacement therapy; low-dose naltrexone; opioid-induced hypogonadism; opioids.

Similar articles

See all similar articles



    1. Cortazzo MH, Fishman SM. Major Opioids and Chronic Opioid Therapy. Amesterdam, Netherland: Elsevier Inc.; 2008:597-611.
    1. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115(6):1363-1381.
    1. Mm M, Cm J. Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol. 2011;164(4):1322-1334.
    1. Stolberg VB. Synthetic Narcotics. Thousand Oaks, CA: SAGE publication; 2011.
    1. Von Korff MR. Long-term use of opioids for complex chronic pain. Best Pract Res Clin Rheumatol. 2013;27(5):663-672.

LinkOut - more resources